ONM-501 

OMN-501 is a nanoparticle based dual-activating STING agonist currently in clinical development for the treatment of cancer. The Phase 1 trial is examining the maximum tolerated dose, minimum effective dose and/or recommended dose for expansion of intratumoral ONM-501 as a monotherapy and in combination with a PD-1 checkpoint inhibitor, cemiplimab, in patients with advanced solid tumors and lymphomas. In the expansion phase of the study patients enroll in one to three indication-specific cohorts to assess safety and activity (NCT06022029).